ebselen and nirmatrelvir

ebselen has been researched along with nirmatrelvir in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (100.00)2.80

Authors

AuthorsStudies
Dou, X; Guo, Z; Huo, T; Jiao, N; Lai, L; Liu, Y; Liu, Z; Lu, Y; Song, S; Su, L; Sun, Q; Wang, B; Wang, C; Xu, G; Yu, Z; Zhang, C; Zhang, L; Zhao, X1
Cheng, Y; Claff, T; Gao, S; Gütschow, M; Jing, L; Kang, D; Liu, X; Müller, CE; Schäkel, L; Song, L; Sträter, N; Sylvester, K; Tavis, J; Tollefson, AE; Toth, K; Weiße, RH; Woodson, M; Yang, M; Ye, B; Zhan, P; Zhang, T1
Chen, N; Hao, H; Lai, M; Li, Z; Liao, Y; Wan, N; Wu, N; Xiao, Y; Yan, H; Ye, H; Yu, W; Zhao, Y1

Other Studies

3 other study(ies) available for ebselen and nirmatrelvir

ArticleYear
Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
    European journal of medicinal chemistry, 2022, Aug-05, Volume: 238

    Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Drug Discovery; Furans; Humans; Hydrazines; Molecular Docking Simulation; Protease Inhibitors; SARS-CoV-2

2022
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
    Journal of medicinal chemistry, 2022, 12-22, Volume: 65, Issue:24

    Topics: Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; Piperazines; Protease Inhibitors; SARS-CoV-2; Viral Nonstructural Proteins

2022
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
    Journal of medicinal chemistry, 2022, 12-22, Volume: 65, Issue:24

    Topics: Animals; Antiviral Agents; COVID-19; Cysteine Endopeptidases; Mice; Molecular Docking Simulation; Papain; Peptide Hydrolases; Protease Inhibitors; Rats; SARS-CoV-2; Viral Nonstructural Proteins; Viral Proteases

2022